Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

Abstract

Our aim was to assess the ability of tocilizumab monotherapy to reduce progressive structural joint damage in rheumatoid arthritis patients at high risk of progression. This study was a subanalysis from a prospective 1-year, multicenter, X-ray-reader-blinded, randomized controlled trial of tocilizumab [Study of Active Controlled Monotherapy Used for… (More)
DOI: 10.1007/s10165-010-0325-3

Topics

2 Figures and Tables

Cite this paper

@inproceedings{Hashimoto2011HumanizedAA, title={Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study}, author={Jun Hashimoto and Patrick Garnero and D{\'e}sir{\'e}e Mfm van der Heijde and Nobuyuki Miyasaka and Kazuhiko Yamamoto and Shinichi Kawai and Tsutomu Takeuchi and Hideki Yoshikawa and Norihiro Nishimoto}, booktitle={Modern rheumatology}, year={2011} }